Viracta Therapeutics Price Prediction
| VIRXDelisted Stock | USD 0.03 0 7.38% |
Momentum 42
Sell Extended
Oversold | Overbought |
Using Viracta Therapeutics hype-based prediction, you can estimate the value of Viracta Therapeutics from the perspective of Viracta Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Viracta Therapeutics to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Viracta because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Viracta Therapeutics after-hype prediction price | USD 0.03 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Viracta |
Viracta Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Viracta Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Viracta Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Viracta Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Viracta Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Viracta Therapeutics' pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Viracta Therapeutics' historical news coverage. Viracta Therapeutics' after-hype downside and upside margins for the prediction period are 0.00 and 16.01, respectively. We have considered Viracta Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Viracta Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Viracta Therapeutics is based on 3 months time horizon.
Viracta Therapeutics Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Viracta Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viracta Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Viracta Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
4.51 | 15.98 | 0.00 | 0.20 | 0 Events / Month | 15 Events / Month | Any time |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.03 | 0.03 | 0.33 |
|
Viracta Therapeutics Hype Timeline
Viracta Therapeutics is at this time traded for 0.03. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.2. Viracta is projected to decline in value after the next headline, with the price expected to drop to 0.03. The average volatility of media hype impact on the company price is insignificant. The price decrease on the next news is expected to be -0.33%, whereas the daily expected return is at this time at -4.51%. The volatility of related hype on Viracta Therapeutics is about 35324.21%, with the expected price after the next announcement by competition of 0.23. About 40.0% of the company outstanding shares are owned by institutional investors. The book value of Viracta Therapeutics was at this time reported as 0.33. The company recorded a loss per share of 1.1. Viracta Therapeutics last dividend was issued on the 3rd of September 2020. The entity had 285:1000 split on the 25th of February 2021. Given the investment horizon of 90 days the next projected press release will be any time. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.Viracta Therapeutics Related Hype Analysis
Having access to credible news sources related to Viracta Therapeutics' direct competition is more important than ever and may enhance your ability to predict Viracta Therapeutics' future price movements. Getting to know how Viracta Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Viracta Therapeutics may potentially react to the hype associated with one of its peers.
Viracta Therapeutics Additional Predictive Modules
Most predictive techniques to examine Viracta price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Viracta using various technical indicators. When you analyze Viracta charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Viracta Therapeutics Predictive Indicators
The successful prediction of Viracta Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Viracta Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Viracta Therapeutics based on analysis of Viracta Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Viracta Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Viracta Therapeutics's related companies.
Story Coverage note for Viracta Therapeutics
The number of cover stories for Viracta Therapeutics depends on current market conditions and Viracta Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Viracta Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Viracta Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Viracta Therapeutics Short Properties
Viracta Therapeutics' future price predictability will typically decrease when Viracta Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Viracta Therapeutics often depends not only on the future outlook of the potential Viracta Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Viracta Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.6 M | |
| Cash And Short Term Investments | 53.7 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |